Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study (STOP-Uveitis)
Sponsor: University of Nebraska
This PHASE1/PHASE2 trial investigates Intermediate Uveitis and Pan-uveitis and is currently ongoing. University of Nebraska leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .